Company · Ownership research

Royalty Pharma plc RPRX

CIK 0001802768

Form 4 transactions dated Sep 1, 2023 to Sep 25, 2026, as reported to the SEC.

Insider trading Initial holdings Institutional holders

This page lists 30 of 36 rows; the complete set is available through the API.

Insider filings on file run through 2026-08-19.

Insider purchases & sales

Purchased: $0.00
Sold: $129.60M

Sep 1, 2023 – Aug 19, 2026
Available records · partial months are marked ·

202610 of 30 preview events · 36 available in 2026

Date	Insider	Activity	Trade value (USD)	% of prior holding
2026-08-18	Hite Christopher EVP & Chairman, Partnering	Sale10b5-1 footnote	$6.00M 100,000 shares sold	21.26% sold LLC holding	▾
2026-08-13	Coyne Terrance P. EVP & CFO	Sale10b5-1 footnote	$645.55K 11,002 shares sold	100.00% sold LLC holding	▾
2026-07-01	Urist Marshall EVP, Research & Investments	Sale10b5-1 footnote	$508.45K 9,099 shares sold	100.00% sold Direct holding	▾
2026-06-30	Hite Christopher EVP & Chairman, Partnering	Sale10b5-1 footnote	$5.65M 100,000 shares sold	17.88% sold LLC holding	▾
2026-06-30	Hite Christopher EVP & Chairman, Partnering	Sale10b5-1 footnote	$1.69M 30,000 shares sold	42.86% sold Direct holding	▾
2026-06-24	Urist Marshall EVP, Research & Investments	Sale10b5-1 footnote	$502.07K 9,098 shares sold	50.00% sold Direct holding	▾
2026-06-23	Hite Christopher EVP & Chairman, Partnering	Sale10b5-1 footnote	$8.16M 150,000 shares sold	21.14% sold LLC holding	▾
2026-05-26	Coyne Terrance P. EVP & CFO	Sale10b5-1 footnote	$3.48M 64,399 shares sold	100.00% sold LLC holding	▾
2026-05-20	Urist Marshall EVP, Research & Investments	Sale10b5-1 footnote	$721.84K 13,684 shares sold	42.92% sold Direct holding	▾
2026-05-14	Urist Marshall EVP, Research & Investments	Sale10b5-1 footnote	$726.14K 13,684 shares sold	30.03% sold Direct holding	▾

Showing 30 / 36 record groups in 2026. The complete set is available through the API.

Royalty Pharma plc · RPRX

Follow the people behind the trades.

Sign in to look up the full history beyond 3 years, use advanced screening & filtering, download CSV, and reach other datasets through the Akkru API.

Download CSV
Earlier filings
Advanced screening & filtering
API & AI access

Already have an account?

＋ New accounts get free API credits to explore data beyond ownership filings.

For AI agents & developers

The initial HTML of this page carries its exact data as script#research-data (JSON): values, units, scope, preview limits and SEC sources. Read it directly, no script or API key needed; script#research-access says what needs an account. For the year shown, this page lists 30 of 36 purchase / sale groups and 26 of 26 other groups; the totals and the monthly series cover the whole window.

Without an account: the last 3 years, with the row caps stated on the page. A free account opens all history on file on these pages and the CSV of what a page shows. Rows beyond the caps and bulk retrieval go through the authenticated API / MCP.

MCP  https://api.akkrudata.ai/mcp

list_insider_transactions
{"ticker":"RPRX","transaction_code":["P","S"],"transaction_form_type":"4","page_size":20}

Connect to MCP with OAuth and follow the returned pagination. Credits and usage limits depend on the account.

MCP endpoint: https://api.akkrudata.ai/mcp
API / MCP documentation: /documents
llms.txt: /llms.txt

Sources, coverage & how to read this data

Figures are as reported to the SEC and merged with later amendments where Akkru could match them. Preview limits apply to what is listed, not to the totals, which come from the complete reported data. Nothing is zero-filled: a missing quarter or month is shown as missing.

Non-cancelled, non-derivative purchase (P) and sale (S) rows dated inside the public window, as reported. Includes open-market and private transactions. Data after the latest filing is not asserted complete and is not zero-filled. A grouped event shares filing, transaction date, security, code, direction, ownership bucket and source. Derivative groups also match underlying security, exercise price, exercise/expiration dates and footnote references. Reported rows are retained; P/S price lots can be grouped. Post-transaction balances are never summed.